Erdosteine Market Size By Application (Bronchitis, Chronic Obstructive Pulmonary Disease, Nasopharyngitis), By End-Use (Pharmaceutical, Contract Manufacturing Companies, Research Institute), Industry Analysis Report, Regional Outlook (U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, China, India, Japan, South Korea, Australia, Brazil, Saudi Arabia, UAE, South Africa), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 - 2025
Published Date: May 2019 | Report ID: GMI3371 | Authors: Kunal Ahuja, Shreya Deb Report Format: PDF
Erdosteine Market size surpassed USD 90 million in 2018 and may expect consumption of over 1.2 kilo tons by 2025.
U.S. Erdosteine Market Size, By Application, 2018 & 2025, (Tons)
Get more details on this report - Request Free Sample PDF
Increasing smoking trends in various delivery forms such as regular cigarettes, vaporisers & electronic cigarettes owing to stressed lifestyles may stimulate erdosteine market size. Regular smoking habits cause outbreaks of common respiratory diseases such as smoker’s cough & bronchitis which leads to mucus thickening as it acts a barrier against allergens and bacteria causing congestions. In 2017, an estimated 14% of the U.S. adults were current cigarette smokers out of which 75% smoked every day. Smoking causes COPD which damages air sacs, airways, and the lining of lungs. Growing usage of tobacco in the age group of 18 to 24 years which accounted for around 16.5% in 2017 which in turn drive the young crowd to try these products. Furthermore, 16 million Americans are diagnosed with COPD and is the leading cause of death in the U.S. Erdosteine improves oxidative stress as it decreases viscoelastic properties and bacterial adhesion to the cell membrane, and a scavenging effect on free oxidant radicals, thereby fuelling the product demand.
Increase in respiratory disease is attributed to the increase in air pollution. People breathing poor air can have coughs and asthma symptoms. Exposure to polluted air directly leads to the development of medical conditions which includes bronchitis, respiratory infections, heart diseases, cancer and strokes. In the EU over 430,000 people die every year prematurely as a result of breathing polluted air. Mucolytic medicines aid in treating symptoms of acute flare ups in diseases such as asthma & chronic bronchitis. Erdosteine is used in manufacturing various pharmaceutical drug to avert these diseases caused by pollution. These drugs also improve lung function owing to its antioxidant and anti-inflammatory properties.
Erdosteine Market, By Application
Erdosteine active pharmaceutical ingredient market size from bronchitis application may surpass USD 45 million up to 2025. Increasing smoking trends in Indonesia, China, India, and Vietnam coupled with changing diet patterns owing to sedentary lifestyles will fuel product demand for bronchitis drugs. Regular smoking habits is the major reason for the chronic symptoms of bronchitis such as excessive production of phlegm in response to bacterial infection caused by irritants in cigarette smoke such as tar, cresol, chromium, lead, nitric oxide, styrene, nicotine, and carbon mono oxide. Increase in active pharmaceuticals market share owing to its antioxidant & antibacterial properties which ameliorates regular smoking effects & reduces larynx and pharynx inflammation, thereby stimulating the industry growth.
Erdosteine market size from chronic obstructive pulmonary disease (COPD) application may register gains close to 6% up to 2025. Increase in air pollution owing to rise in manufacturing & automobile sector will boost market growth. Rise in air contaminants reduces the elastase inhibitory capacity in lungs and promotes pathogenic bases propagation which is the major cause for COPD such as emphysema and refractory asthma. Rising cases of immunosuppressed individuals owing to allergies will increase the risk of common respiratory problems such as common cold & nasopharyngitis which in turn may accelerate the overall market size.
Erdosteine Market, By End Use
Erdosteine market demand from pharmaceutical sector was valued at over USD 40 million in 2018. Increasing respiratory diseases cases owing to rise in air contaminants such as particulate matter, nitrogen oxides, sulphur oxides, nitrates, ground level ozone, volatile organic compounds, and carbon mono oxides will boost the industry. These contaminants increase the risk of bacterial infections which triggers excessive mucus production thus causing severe congestions and respiratory problems. Erdosteine is available in sachet, suspension, capsule and dispersible tablet forms which has benefitted the healthcare authorities and companies for the effective diagnosis and prevention of COPD and bronchitis. Increasing aging population and the rising number of individuals diagnosed with the chronic illnesses such as cardiac disorders, diabetes, and respiratory diseases may boost the pharmaceutical market.
Research institutes end-use segment may grow significantly at over 5.5% over the forecast timeframe. Rise in technological and medical research trends across top universities in the U.S. and Europe such as John Hopkins Medical School, Harvard Medical School, Cambridge School of Clinical Studies and Columbia University will stimulate the overall market share. Various clinical studies across labs are underway to substantiate the efficacy for mucolytic based drugs in various respiratory and cardiovascular diseases. Increase in private & government funding across various medical research segments will stimulate the market growth.
Erdosteine Market, By Region
North America, driven by Canada and the U.S. erdosteine market size may register significant growth over 6% up to 2025. Growing consumer consciousness towards clinical efficacy and low side effect characteristics of medicines may drive regional market. Favourable regulation by FDA regarding organ drug approval and its usage for treating various COPD’s such as refractory bronchitis and emphysema is likely to drive industry growth.
Europe driven by UK, France, and Germany erdosteine industry demand may surpass USD 45 million by 2025. Increasing geriatric population and extreme winter temperatures will boost the overall market in the region. Extreme winters in Europe and rising cases of weak immune systems will increase the prevalence of common cold. EU Commission adopted regulations regarding clinical efficacy and safety of mucolytic drugs before authorizing in the market.
Asia Pacific led by India, Japan, and China market size was valued at over USD 20 million in 2018. Rapid industrialization, population growth and increase in smoking trends owing to sedentary lifestyles will boost the regional market demand for respiratory drugs. Rising asthma & bronchitis cases owing to increase in pollution level of metropolitan cities from vehicle and factory smoke in India and China will increase cheap & over the counter drugs demand owing to its anti-inflammatory and free radical scavenging properties.
Competitive Market Share
Global erdosteine market share is consolidated with five market participants accounting for over 85% of the total market share in 2018. Recipharm AB, Hikma Pharmaceuticals, Delta Finochem, Shandong Luoxin Pharmaceutical, and Hanmi Pharmaceuticals are the major industrial participants. Companies are involved in research and new product development to diversify their product portfolio and widen geographical presence. Furthermore, manufactures are focusing to cost effective products within stringent regulations to foster overall erdosteine industry growth.
Get more details on this report - Request Free Sample PDF
Erdosteine is a mucolytic agent which aids in mucus & phlegm clearance from bronchi, trachea, and lungs. It is used to treat symptoms pertaining to excessive mucus production triggered through smoking habits, environment contaminates like smoke from cars & industries, pollen, ground level ozone, and volatile organic compounds. Its easy availability, easy manufacturing methods, economic nature, and low side effects will fuel product demand.
What Information does this report contain?